About Nucleotide sugar transporter SLC35D1
Nucleotide sugar transporter SLC35D1 (SLC35D1) is a protein
from Homo sapiens identified by UniProt accession
Q9NTN3, 355 residues long.
MolForge cross-references it against 0 known binders and
147 disease associations.
Target properties
| Protein name | Nucleotide sugar transporter SLC35D1 |
|---|
| UniProt accession | Q9NTN3 |
|---|
| Gene | SLC35D1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 355 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (147)
Diseases linked to this target (Open Targets).
- schneckenbecken dysplasia · score 0.80
- lymphocyte count · score 0.44
- neurodegenerative disease · score 0.39
- leukocyte count · score 0.37
- monocyte count · score 0.29
- thalamus volume · score 0.27
- myeloid white cell count · score 0.26
- sex hormone-binding globulin measurement · score 0.26
- lymphocyte percentage of leukocytes · score 0.24
- body height · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NTN3-F1 | alphafold | PREDICTED | 80.98 | — |
Amino-acid sequence (355 residues)
MAEVHRRQHA RVKGEAPAKS STLRDEEELG MASAETLTVF LKLLAAGFYG VSSFLIVVVN KSVLTNYRFP SSLCVGLGQM VATVAVLWVG KALRVVKFPD LDRNVPRKTF PLPLLYFGNQ ITGLFSTKKL NLPMFTVLRR FSILFTMFAE GVLLKKTFSW GIKMTVFAMI IGAFVAASSD LAFDLEGYAF ILINDVLTAA NGAYVKQKLD SKELGKYGLL YYNALFMILP TLAIAYFTGD AQKAVEFEGW ADTLFLLQFT LSCVMGFILM YATVLCTQYN SALTTTIVGC IKNILITYIG MVFGGDYIFT WTNFIGLNIS IAGSLVYSYI TFTEEQLSKQ SEANNKLDIK GKGAV
Explore Nucleotide sugar transporter SLC35D1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets